Company intelligence / Profile preview
TriArm Therapeutics
Shanghai, Chinatriarmbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TriArm Therapeutics is running multiple early-phase clinical trials (highest stage: Phase 1) using proprietary non-viral gene transfer technologies to reduce CAR-T manufacturing time and cost, targeting solid and hematologic malignancies. Programs are currently in Phase 1 or IND-stage, with early data supporting clinical feasibility and safety, but no later-stage (Phase 2/3) clinical readouts yet.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cell therapyCell therapyT cell receptor engineered T cell therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on TriArm Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriArm Therapeutics.